Download PDF 673KB

▲
▲
▲
▲
▲
▲
先端医療機器開発のフロンティア
──先端センター
（CRCMeD）
プロジェクト紹介
CLINICAL
RESEARCH CENTER FOR MEDICAL EQUIPMENT
DEVELOPMENT (CRCMeD)
– Projects for
Medical Equipment Development Frontiers
Development of Next-Generation Mass Spectrometry System and Contribution toward Drug Discovery and Diagnostics
State-of-the-Art Proteomics Research
for Solutions to Medical Needs
Kyoto University is currently taking part in the Funding Program for WorldLeading Innovative R&D on Science and Technology (FIRST Program).
As part of the Program, this project will develop next-generation mass
spectrometry in the leading-edge proteomics research field and explore
disease biomarkers for innovative diagnostic solutions and drug development for improved quality of life.
Next-Generation DIT-MALDI/TOF
Mass Spectrometry System for World’s
Highest-Sensitivity Measurements
The mass spectrometry system is the only analyzer that
enables extremely high-sensitivity detection and quantification of trace amounts of biomarkers that can dramatically
change according to the state of a disease. In the FIRST Program, a next-generation DIT-MALDI/TOF MS system has
been newly developed to enable ultra high-sensitivity measurements, 100 to 1,000 times higher than what is possible with
conventional techniques. The Center uses the system to analyze clinical samples. Expectations are high that the MS system
will have the ability to detect ultra-trace amounts of biomarkers, a capacity that has
never before been possible. A triple quadrupole LC-MS system
will also be installed for
quantitative analysis of
ultra-trace amounts of
molecules.
▲ Next-generation DIT-MALDI/TOF MS system
Kyoto University Hospital　CRCMeD
Graduate Schools of Medicine and
Pharmaceutical Sciences,
Kyoto University
Shimadzu Corporation
Link
http://www.first-ms3d.jp/
Mass Spectrum
5mm
Mouse Brain Section
100μm
Optical Image
MALDI MS Images
▲ Detailed image
of analysis results
Prototype MS
imaging analyzer
▲
The Graduate School of Medicine and the Graduate
School of Pharmaceutical Sciences of Kyoto University together with Shimadzu Corporation are jointly implementing
a project called Development of the Next-Generation Mass
Spectrometry System and Contribution toward Drug Discovery and Diagnostics (core researcher: TANAKA Koichi, Shimadzu Corporation) under the FIRST Program. The goal of
this project is to develop a next-generation mass spectrometry
(MS) system that will deliver the world’s highest performance
yet. A system will be implemented for the detection of cancer
biomarkers and candidate target molecules for drug development. The key equipment, a next-generation high-sensitivity
DIT-MALDI/TOF mass spectrometry system, is accompanied by a prototype high-resolution imaging mass spectrometry system that combines the most advanced techniques and
clinical research for the development of analysis technology
and candidate target molecules.
Participants
Epoch-Making Imaging Mass Spectrometry System
That Makes In Vivo Distribution of
Substances Visible
Imaging of the in vivo distribution of substances is a leading-edge technology that has become a focus of world attention. The technology is realized in the revolutionary imaging
mass spectrometry system, which, with some 10-micrometer
resolution, recognizes various substances in individual microscopic portions of body tissue, analyzes them at the molecular
level, and eventually creates detailed images of the entire tissue at the molecular level. MS imaging analysis makes it possible to identify specific, individual molecules present in tissues,
providing information on their disposition and localization in
tissue in the form of two-dimensional data. The world’s first
prototype equipment developed by Shimadzu Corporation is
being implemented to realize this project.
With these two leading-edge mass spectrometry technologies,
namely ultra high-sensitivity MS analysis and MS imaging analysis, the Center intends to explore and identify truly useful disease
biomarkers and candidate target molecules as a way of making a
contribution to the fields of life sciences and medical care.
Grand Expectations for CRCMeD
Molecular bioanalysis can contribute to medical care only when it is
applied to clinical samples. Conventionally, many difficulties arose in
the use of state-of-the-art analysis technologies closely linked to the
field of medical care and related areas. The Center has been designed
to overcome all such difficulties and expectations are high that it
will advance to become a leading-edge research base, active in the
development of both clinical analysis technology and equipment.
▲
▲
▲
▲
Clinical Research Center for Medical Equipment Development　http://crcmed.kuhp.kyoto-u.ac.jp